Kordata Launches To Advance Neurotech-Powered Clinical Trials
Kordata Dynamics, a company that has recently emerged from stealth mode, is set to revolutionize the clinical trials backlog in central nervous system (CNS) therapeutics. With a focus on patient-facing neurotechnology and an enterprise B2B strategy, Kordata aims to tap into a $26 billion opportunity in the healthcare sector.
The core IP and business foundation for Kordata were supplied by BIOS Health, with majority ownership retained by the parent company. Emil Hewage, the founder of both firms, will lead Kordata as CEO, supported by president Dawn McCollough, a seasoned executive with extensive experience in clinical trials.
In a recent interview with Hewage, he outlined Kordata’s business model, which involves partnering with large health systems and academic medical centers to facilitate new trial sites for pharmaceutical and life sciences companies. By deploying tools to these networks and securing new clinical trial sponsorships, Kordata aims to generate revenue through volume-based licensing and fees.
The target market for Kordata includes life sciences firms looking to design novel trials for precise products with unique criteria. Initially focusing on CNS disorders like Alzheimer’s, Parkinson’s, and Epilepsy, Kordata also sees potential in addressing drug-resistant chronic diseases in other therapeutic areas.
One of Kordata’s key offerings is its Tech Stack as a Service, which provides health system partners with the capability to run large trials efficiently. By leveraging BIOS’ NeuroTune platform, Kordata enables real-time dosing based on individual patient responses, allowing for personalized treatment approaches.
At a recent private launch event, Kordata attracted a diverse group of industry leaders, investors, and stakeholders, signaling a strong interest in the company’s innovative approach. Based in Bakersfield, CA, Kordata is strategically positioned to collaborate with public payers and clinical sites, facilitating access to a broad patient population for its partners.
The emergence of Kordata comes at a time when AI and neurotechnology are reshaping the biotech landscape, paving the way for new approaches in drug discovery and clinical research. With initiatives like the FDA’s real-time clinical trials program and advancements in neurotech market leaders, the prospects for innovation in CNS therapeutics are bright.
As the healthcare industry embraces new technologies and collaborative models, companies like Kordata are poised to drive significant advancements in patient care and treatment outcomes. By harnessing the power of neural data and cutting-edge technology, Kordata is at the forefront of a new era in healthcare innovation.
